UBS has downgraded SCHOTT Pharma's stock rating from 'Buy' to 'Neutral' and lowered its price target, citing concerns about decreased demand for glass syringes. This adjustment follows a revised forecast from a competitor, indicating a potentially challenging market environment for SCHOTT Pharma through fiscal year 2027/28.
UBS downgraded SCHOTT Pharma to 'Neutral' and cut its price target due to anticipated decreased demand for glass syringes, a core product. This revision was prompted by a competitor's (Stevanato) updated forecast, suggesting a broader industry trend rather than an isolated issue for SCHOTT Pharma. The downgrade implies a challenging outlook for SCHOTT Pharma's revenue and profitability through fiscal year 2027/28, potentially leading to short-term negative pressure on its stock. For traders, this signals a need to re-evaluate SCHOTT Pharma's growth prospects and consider potential downside risk, especially given the long-term nature of the demand concerns.